Inhibition of airway inflammation in rDer f 2-sensitized mice by oral administration of recombinant der f 2.
Recombinant Der f 2 (rDer f 2) is a promising new allergen expected to improve the diagnosis and immunotherapy of house dust mite allergy and to further immunological studies. To evaluate the hyposensitizing activity of rDer f 2 to mite allergy, we examined the effect of its oral administration on allergic inflammation in A/J mice immunized with mite allergens. A/J mice immunized with rDer f 2 alone or rDer f 2 + crude mite extract were orally given 0 (control), 0.01, 0.1, or 1 mg/day of rDer f 2 for 4 weeks, followed by an antigen inhalation challenge. Twenty-four hours after rDer f 2 inhalation, control animals experienced severe leukocyte influx into the airway. The infiltrating cells were mainly neutrophils, with some eosinophils and lymphocytes. The concentrations of IL4, IFNgamma, and soluble ICAM-1 in the bronchial alveolar lavage fluid increased twofold compared with values before rDer f 2 inhalation. In contrast, inflammation was significantly suppressed in mice given 1 mg/day of rDer f 2 orally for 4 weeks and partially suppressed in those fed 0.1 mg/day of the antigen. Plasma anti-rDer f 2 antibody levels were unchanged by oral rDer f 2 treatment. Mite extract inhalation challenge provoked neutophilia in rDer f 2 + mite-sensitized control mice, and this allergic reaction tended to decrease in sensitized mice fed 1 mg/day of rDer f 2 orally for 4 weeks. We conclude that rDer f 2 has hyposensitizing activities and may be useful in immunotherapy for house dust mite allergy.
Yasue
M
M
Bioscience Research and Development Laboratory, Asahi Breweries Ltd., 1-21, Midori 1-Chome, Moriya-machi, Ibaraki, 302-0106, Japan.
Yokota
T
T
Kajiwara
Y
Y
Suko
M
M
Okudaira
H
H
D000284:Administration, Oral; D000485:Allergens; D000818:Animals; D039741:Antigens, Dermatophagoides; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology*; D006967:Hypersensitivity / Q000276:immunology* / Q000517:prevention & control; D007114:Immunization; D007249:Inflammation / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D008925:Mites; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D012137:Respiratory System / Q000276:immunology* / Q000473:pathology
D000485:Allergens; D039741:Antigens, Dermatophagoides; D006023:Glycoproteins; D011994:Recombinant Proteins